Shalini C Reshmi

List of Publications by Year
in descending order

32 papers	2,738 citations	567281 15 h-index	434195 31 g-index
32 all docs	32 docs citations	32 times ranked	4056 citing authors

#	Article	IF	Citations
1	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
2	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
3	Targetable kinase gene fusions in high-risk B-ALL: a study from the Childrenâ€™s Oncology Group. Blood, 2017, 129, 3352-3361.	1.4	236
4	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	12.8	218
5	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
6	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 29, 186-200.	16.8	118
7	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Childrenâ€™s Oncology Group. Blood, 2018, 132, 815-824.	1.4	97
8	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€•or â€œBCR-ABL1-Likeâ€) Signature For Therapeutic Targeting and Clinical Intervention. Blood, 2013, 122, 826-826.	1.4	65
9	Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum. American Journal of Human Genetics, 2020, 107, 499-513.	6.2	48
10	Variability in pathogenicity prediction programs: impact on clinical diagnostics. Molecular Genetics & Genomic Medicine, 2015, 3, 99-110.	1.2	44
11	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Advances, 2018, 2, 529-533.	5.2	34
12	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	21.4	29
13	Reclassification of Variants of Uncertain Significance in Children with Inherited Arrhythmia Syndromes is Predicted by Clinical Factors. Pediatric Cardiology, 2019, 40, 1679-1687.	1.3	24
14	Neurodevelopmental disorders among individuals with duplication of 4p13 to 4p12 containing a GABAA receptor subunit gene cluster. European Journal of Human Genetics, 2014, 22, 105-109.	2.8	20
15	Disease-associated mosaic variation in clinical exome sequencing: a two-year pediatric tertiary care experience. Journal of Physical Education and Sports Management, 2020, 6, a005231.	1.2	15
16	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	1.4	14
17	Genomic analysis of adult B-ALL identifies potential markers of shorter survival. Leukemia Research, 2017, 56, 44-51.	0.8	12
18	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. Blood, 2009, 114, 1580-1580.	1.4	7

#	Article	IF	Citations
19	Atypical breakpoint in a t(6;17) translocation case of acampomelic campomelic dysplasia. European Journal of Medical Genetics, 2014, 57, 315-318.	1.3	6
20	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. Blood, 2020, 136, 45-46.	1.4	6
21	Inherited and de novo variants extend the etiology of TAOK1-associated neurodevelopmental disorder. Journal of Physical Education and Sports Management, 2022, , mcs.a006180.	1.2	6
22	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
23	Functional Analysis of Kinase-Activating Fusions in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 786-786.	1.4	3
24	Immune Reconstitution after Hematopoietic Stem Cell Transplantation in Immunodeficiencyâ€“Centromeric Instabilityâ€“Facial Anomalies Syndrome Type 1. Journal of Clinical Immunology, 2021, 41, 1089-1094.	3.8	2
25	5â€² <i>ALK</i> Amplification in Neuroblastoma: A Case Report. Case Reports in Oncology, 2021, 14, 585-591.	0.7	2
26	International Laboratory Comparison of Methodologies for Determining Minimal Residual Disease (MRD) in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood, 2015, 126, 2612-2612.	1.4	2
27	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. Blood, 2020, 136, 39-40.	1.4	2
28	Pericentromeric regions of homozygosity on the X chromosome: Another likely benign population variant. European Journal of Medical Genetics, 2018, 61, 416-420.	1.3	1
29	Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival. Blood, 2015, 126, 1427-1427.	1.4	1
30	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). Blood, 2020, 136, 44-45.	1.4	1
31	Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study.. Journal of Clinical Oncology, 2022, 40, 10023-10023.	1.6	1
32	Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia. , 2021, , .		0